BioWorld

May 7, 2008

Apoptos Targeting Cell Death with $28M Series A Financing

Year-old Apoptos Inc. is raising $28 million in its first major funding round since being established in June 2007 by venture firms Venrock and ARCH Ventures based on technology targeting programmed cell death. (BioWorld Today) Read More

FDA Panel Advises Against Wider Marketing of Fentora

New Data on MedImmune, AVI BioPharma RSV Drugs

Merck Cost-Cutting Could Be Boon for Biotech Firms

Pfizer Pullout Sends NicOx Shares Down

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for May 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Concept art for "unlocking the secrets of the mind"

New assay for drug discovery against chemo-induced peripheral neuropathy

BioWorld Science

A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...